Inking the Deal

Mastering the art of lasting outsourcing relationships in the pharmaceutical industry

PM1701 NAV

Responsible drug manufacturers and contract organizations share the common goal of producing the best possible product in the most efficient way. The two have shared mutually beneficial relationships for decades in the pharmaceutical industry and will no doubt continue to do so for years to come. The numbers support that continued success as well: according to an IntelliROI 2016 report, the global contract pharmaceutical manufacturing market is expected to reach $84 billion by 2020, up from $58 billion in 2014. What follows is an in-depth look at pharma’s outsourcing relationships from the contract manufacturing perspective — what works, what doesn’t, and how to…

Full Story

Don't Miss These Pharma Manufacturing Exclusives

Fundamentals

On-demand, concise audio and powerpoint tutorials on the fundamental concepts of pharmaceutical manufacturing, process development, quality control and compliance.

Ask the Expert

We've assembled a roster of leading authorities in many fields to help you address technical issues. Pose a question or browse previous questions to find helpful answers.

Funny Pharm

Write a caption and win!

Aug15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • Outsourcing Relationships Even Mom Will Love

    By Karen Langhauser, Chief Content Director

    When I got my first tattoo in college, I didn’t have any of the typical “first ink” worries (What if it hurts? What if I change my mind a year later? What will it look like when I’m OLD?) Nope. My biggest fear was the wrath of my mother once she saw it. I’m pretty sure I wore a bracelet…

    Full Story
  • The Evolving Biopharma Contract-Manufacturing Market

    By Andrea Gennari, Martin Loesch, Alberto Santagostino and Ralf Otto, McKinsey & Co.

    Biopharma companies have depended on contract manufacturing organizations (CMOs) to provide capacity and capabilities as needed; in some cases, CMOs have provided a great deal of a company’s production. Yet the current market structure presents biopharmacos with a shortage of CMO capacity to…

    Full Story
  • Inking the Deal

    By Karen Langhauser, Chief Content Director

    Responsible drug manufacturers and contract organizations share the common goal of producing the best possible product in the most efficient way. The two have shared mutually beneficial relationships for decades in the pharmaceutical industry and will no doubt continue to do so for years to come.

    Full Story
  • FDA Gathers Faster Drug Data

    By Katie Weiler, Managing Editor

    Many would agree that “fast” doesn’t often describe the U.S. Food and Drug Administration. But the agency is taking steps to change its reputation and expedite some of its pharmaceutical drug processes.For example, the FDA says it is now making it easier and faster for health care…

    Full Story
  • Electronic Batch Records: Improving Compliance, Accelerating Time to Market

    By Chris Frost, Dassault Systèmes BIOVIA

    The pharmaceutical and biotechnology industries have been bound by strict regulations for a long time. In fact, few other industries must contend with such high levels of control, transparency and traceability. In pharmaceutical manufacturing, these high levels of compliance and quality are…

    Full Story
  • Streamlining Single-Use Processing on a Global Scale

    By Todd Andrews, bioprocessing business unit, CPC

    Given the estimated $1 billion1 price tag of bringing a drug to market, biologic and pharmaceutical manufacturers increasingly rely upon single-use aseptic processing systems for more flexible, reliable and cost-effective operations. Too often, though, individual manufacturing sites within large,…

    Full Story

Latest Products